Market Overview - The plastic sector experienced a decline of 2.57% on August 27, with Yuxing Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers in the plastic sector included: - Anli Co., Ltd. with a closing price of 25.64, up 13.05% and a trading volume of 388,600 shares, totaling 994 million yuan [1] - Weike Technology with a closing price of 99.00, up 6.46% and a trading volume of 103,900 shares, totaling 1.033 billion yuan [1] - Major decliners included: - Yuxing Co., Ltd. with a closing price of 6.39, down 7.53% and a trading volume of 150,700 shares, totaling 100 million yuan [2] - Nanjing Jinglong with a closing price of 35.50, down 7.09% and a trading volume of 126,100 shares, totaling 465 million yuan [2] Capital Flow - The plastic sector saw a net outflow of 1.621 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.314 billion yuan [2] - The table of capital flow indicates that: - Qide New Materials had a net inflow of 28.57 million yuan from institutional investors, while retail investors had a net outflow of 27.24 million yuan [3] - Anli Co., Ltd. experienced a net inflow of 17.96 million yuan from institutional investors, with a net outflow of 29.36 million yuan from retail investors [3]

浙江海正生物材料股份有限公司 关于 5%以上股东提前终止减持计划暨减持股份结 果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688203 证券简称：海正生材 公告编号：2025-49 大股东持股的基本情况 本次减持计划实施前，浙江海正生物材料股份有限公司（以下简称"公司" 或"海正生材"）持股 5%以上股东中国石化集团资本有限公司（以下简称"中 石化资本"）持有公司股份 13,659,494 股，占公司总股本的 6.74%。上述股份 为公司首次公开发行前取得的股份，并已于 2024 年 2 月 19 日起上市流通。 减持计划的实施结果情况 公司于 2025 年 7 月 1 日披露了《浙江海正生物材料股份有限公司股东减持 股份计划公告》（公告编号：2025-35）。公司股东中石化资本拟通过大宗交易 方式减持公司股份不超过 3,525,600 股，占公司总股本比例不超过 1.74%。 2025 年 8 月 26 日，公司收到中石化资本的告知函，中石化资本通过大宗交 易方式已累计减 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东持股的基本情况 证券代码：688203 证券简称：海正生材 公告编号：2025-49 浙江海正生物材料股份有限公司 关于 5%以上股东提前终止减持计划暨减持股份结 果公告 股东名称 中国石化集团资本有限公司 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 √是 □否 股东身份 董事、监事和高级管理人员 □是 √否 其他：/ 持股数量 13,659,494股 持股比例 6.74% 当前持股股份来源 IPO 前取得：13,659,494股 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 其他情形：减持计划提前终止 股东名称 中国石化集团资本有限公司 减持计划首次披露日期 2025 年 7 月 1 日 减持数量 844,600股 减持期间 2025 年 8 月 22 日～2025 年 8 月 22 日 减持方式及对应减持数量 大宗交易减持，844,600 股 减持价格区间 11 ...

南财智讯8月26日电，海正生材公告，中国石化集团资本有限公司作为持有公司5%以上股份的股东，原 计划通过大宗交易方式减持不超过352.56万股，占公司总股本的1.74%。截至2025年8月22日，实际减持 84.46万股，占公司总股本的0.42%，减持总金额为980.58万元。因自身发展计划和资金安排，中国石化 集团资本有限公司决定提前终止本次减持计划。减持后，中国石化集团资本有限公司持有公司1281.49 万股，占公司总股本的6.32%。 ...

| 成交量 | 成交金 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | | | | | 50.00 | 580.50 | 11.61 | -18.92 | 广发证券股份有限公司佛 山灯湖东路证券营业部 | 中国中金财富证券有限公司 北京建国门外大街证券营业 | | | | | | | 部 | | 17.23 | 200.04 | 11.61 | -18.92 | 中信建投证券股份有限公 司北京望京证券营业部 | 中国中金财富证券有限公司 北京建国门外大街证券营业 | | | | | | | 部 | | 17.23 | 200.04 | 11.61 | -18.92 | 国投证券股份有限公司连 | 中国中金财富证券有限公司 北京建国门外大街证券营业 | | | | | | 云港郁州北路证券营业部 | | | | | | | | 部 | 海正生材8月22日大宗交易平台共发生3笔成交，合计成交量84.46万股，成交金额980.5 ...

Summary of Key Points Core Viewpoint - The stock of Hai Zheng Sheng Cai experienced a slight decline of 0.07% on August 22, closing at 14.32 yuan, with significant block trades occurring totaling 980.58 million yuan [1]. Trading Activity - A total of three block trades were executed, with a combined trading volume of 844,600 shares [1]. - The first trade was priced at 11.61 yuan for 172,300 shares, amounting to 2 million yuan, with a discount rate of -18.92% [1]. - The second trade also occurred at 11.61 yuan for 500,000 shares, totaling 5.81 million yuan, maintaining the same discount rate of -18.92% [1]. - The third trade mirrored the first, priced at 11.61 yuan for 172,300 shares, again totaling 2 million yuan, with the same discount rate [1]. Recent Performance - Over the past three months, the stock has seen a total of three block trades with a cumulative transaction value of 980.58 million yuan [2]. - In the last five trading days, the stock has increased by 7.35%, although there has been a net outflow of 3.90 million yuan in principal funds [2].

| 交易日期 | 豆瓣圆修 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 英入管业部 | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-22 | 海正生材 | 688203 | 11.61 | 580.5 | 50 | 广发适劳股份有限 公司佛山灯温东路 | 中国中金财富证券 有限公司北京建国 | 198 | | | | | | | | 挺登显不完 | []外大街证券营业 | | | | | | | | | | - | | | 2025-08-22 | 海正生材 | 688203 | 11.61 | 200.04 | 17.23 | 中信建投证券股份 | 中国中金财富证券 | | | | | | | | | 有限公司北京望京 | 有限公司北京建国 | | | | | | | | | 证券营业部 | 门外大街证券营业 | | | | | | | | | | 部 : 100 | | | 2025-08-22 | 海正生材 | 688203 | 11.61 | 200. ...

Summary of Haizheng Biomaterials Conference Call Company Overview - **Company**: Haizheng Biomaterials - **Industry**: Bioplastics, specifically focusing on polylactic acid (PLA) production Key Financial Performance - **Revenue**: In the first half of 2025, revenue decreased by 87.32% year-on-year to 408 million yuan [2][3] - **Net Profit**: Net profit fell by 87.32% to 3.1815 million yuan, with non-recurring net profit down 88.82% to 2.3461 million yuan [2][3] - **Product Pricing**: Average product prices dropped by 7.5% compared to the previous year, impacting overall revenue [3] Production and Sales Insights - **PLA Production**: Pure PLA production was approximately 25,000 tons, with a subsidiary's production line operating at 88.45% capacity [2][4] - **Sales Growth**: Pure PLA sales increased by over 7%, while modified PLA sales slightly declined [4] - **3D Printing Market**: The 3D printing sector saw significant growth, with sales increasing by 138% in the 3D printing field and 55% in extrusion thermoforming [2][4][6] Market Trends and Projections - **3D Printing Demand**: The demand for PLA in the 3D printing sector is expected to reach 100,000 tons by 2026, with PLA maintaining a leading position in this market [6] - **Future Supply and Demand**: The industry is currently facing an oversupply situation, with domestic and international production capacity totaling approximately 260,000 tons against a demand of only 120,000 tons [17] Competitive Landscape - **Domestic Competitors**: Major domestic PLA manufacturers include Haizheng, Jinhua, Prilis, Lianheng, and Huitong, each with varying production capacities [7] - **Market Share**: Haizheng holds a production capacity of 60,000 tons and is testing a new project with an additional 75,000 tons [7] Profitability and Cost Management - **Gross Margin Improvement**: The gross margin improved in Q2 due to increased production and a slight decrease in raw material prices [8] - **Price Stability Outlook**: The company believes PLA prices are nearing the cost floor, with potential declines if supply exceeds demand [8] Export and International Market Dynamics - **Export Challenges**: The company faced significant export challenges due to US-China trade tensions, with tariffs impacting product pricing and customer behavior [11][12] - **Market Performance**: The European market remained stable but did not meet purchasing expectations, while the Indian market showed positive performance with good order signings [12] Technological and Product Development - **3D Printing Material Requirements**: The 3D printing sector has specific performance requirements for PLA materials, which domestic competitors struggle to meet [25] - **Future Applications**: There is potential for PLA to expand into new applications, including specialty fibers and construction materials, despite current oversupply issues [18] Strategic Considerations - **Market Entry Plans**: Haizheng is not currently planning to enter the medical-grade PLA market due to certification requirements [14] - **R&D Investments**: The company is actively investing in R&D to enhance material performance and explore new applications [16][23] Conclusion - Haizheng Biomaterials is navigating a challenging market environment with significant revenue declines but is positioned for potential growth in the 3D printing sector. The company is focusing on improving production efficiency, managing costs, and exploring new market opportunities while facing competitive pressures and export challenges.

Core Viewpoint - The article discusses the financial performance and operational updates of Haizheng Biomaterials for the first half of 2025, highlighting a decline in revenue and profit due to reduced product prices and lower interest income and government subsidies [2][3]. Financial Performance - Haizheng Biomaterials reported a revenue of 408.21 million yuan, a decrease of 5.28% year-on-year [3]. - The total profit for the period was 9.38 million yuan, down 69.14% compared to the previous year [3]. - The net profit attributable to shareholders was 3.18 million yuan, reflecting an 87.32% decline [3]. - The net profit after deducting non-recurring gains and losses was 2.35 million yuan, a decrease of 88.82% [3]. - The net cash flow from operating activities was 18.12 million yuan, an increase of 174.86% year-on-year [3]. - As of the end of the reporting period, the net assets attributable to shareholders were 1.48 billion yuan, a decrease of 0.95% from the previous year [3]. Product and Production Updates - The main product of Haizheng Biomaterials is resin-based polylactic acid (PLA), which is categorized into pure PLA and modified PLA [4]. - In the first half of 2025, the company produced 24,100 tons of pure PLA resin, achieving a capacity utilization rate of over 80% [4]. - PLA sales increased by 2.85% year-on-year, with domestic sales rising by 12.52% [4]. - The 3D printing sector saw a significant growth of 136% compared to the same period last year, while the extrusion thermoforming sector's sales grew by 55% [4]. Project Development - The construction of a new project with an annual capacity of 150,000 tons of PLA is underway, with the first phase expected to be completed by December 2025 and the second phase by December 2028 [4]. - As of the reporting period, the civil engineering for the 150,000-ton project is nearly complete, and the first phase's production line has been installed and is operational [4]. Research and Development - The company invested 15.47 million yuan in R&D during the reporting period, a 7.35% increase year-on-year [4]. - Several projects have entered the pilot testing stage, and some new products have gained customer recognition and orders [4]. - Research is being conducted in new areas, including: - Research on isotactic composite PLA, which enhances heat resistance by over 30°C compared to conventional processes [5]. - Development of flexible biaxially stretched films that maintain transparency and biodegradability while improving toughness [5]. - Low-cost PLA-based 3D printing materials that enhance heat resistance and interlayer bonding [5]. - Skin-core structured PLA fibers that offer multifunctional properties for various applications [5].

Group 1 - The company has adjusted the maximum repurchase price from 12 RMB per share to 17 RMB per share and extended the implementation period by 6 months, now ending on February 27, 2026 [16][21][36] - The repurchase plan aims to use self-owned funds and may include special loans for stock repurchase [19][20] - As of the disclosure date, the company has repurchased 1,482,364 shares, accounting for 0.731% of the total share capital, with a total expenditure of approximately 14.29 million RMB [20][21] Group 2 - The company raised a total of 845.17 million RMB from the public offering, with a net amount of 750.86 million RMB after deducting various fees [2][4] - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory requirements [4][5] - The company has not encountered any abnormal situations regarding the investment projects funded by the raised capital [7][8]